Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06760637 · ClinicalTrials.gov registry record · Phase 3
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
A Phase 3 study of Breast Cancer, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,020
- Enrollment target
- 20
- Study locations
NCT06760637: Recruiting Phase 3 study of Breast Cancer, sponsored by Pfizer.
NCT06760637 is a Phase 3 study of Breast Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 1,020 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06760637, a Phase 3 study of Breast Cancer, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,020 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.
Primary Outcome
Time from the date of randomization to the date of the first documentation of objective progressive disease as determined by blinded independent central review (BICR) per RECIST v1.1, or death due to any cause, whichever occurs first
Conditions Studied
Interventions
- DRUG abemaciclib
- DRUG PF-07220060
- DRUG letrozole
- DRUG palbociclib
- DRUG ribociclib
Study Locations (20)
Arkansas
- CARTI Cancer Center Saline County - Bryant
- CARTI Cancer Center Conway - Conway
- Highlands Oncology - Fayetteville
- CARTI Cancer Center - Little Rock
- CARTI Cancer Center North Little Rock Urology - North Little Rock
- CARTI Cancer Center North Little Rock - North Little Rock
- CARTI Cancer Center Pine Bluff - Pine Bluff
- Highlands Oncology - Rogers
- Highlands Oncology Group - Springdale
Arizona
- Ironwood Cancer & Research Centers - Chandler
- Ironwood Cancer & Research Centers - Gilbert
- Ironwood Cancer & Research Centers - Glendale
- Ironwood Cancer & Research Centers - Goodyear
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Mesa
- Ironwood Cancer & Research Centers - Phoenix
- Ironwood Cancer & Research Centers - Scottsdale
Alabama
- The Kirklin Clinic of UAB Hospital - Birmingham
- The University of Alabama at Birmingham - Birmingham
- University of Alabama at Birmingham Hospital - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2037-12-29 |
| Phase | Phase 3 |
What NCT06760637 shows while recruiting
NCT06760637 is an interventional study that assigns participants to a tested intervention. Its 1,020 participants enrollment target places it among the larger protocols in the corpus, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which abemaciclib is the first listed.
NCT06760637 names 20 study sites across 3 states, led by Arkansas, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06760637 about?
NCT06760637 is a clinical study titled "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease". The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * ...
What is the current status of trial NCT06760637?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,020 participants. The study started on 2025-01-06. Estimated completion is 2037-12-29.
What conditions does trial NCT06760637 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT06760637?
The interventions under investigation include: abemaciclib (DRUG), PF-07220060 (DRUG), letrozole (DRUG), palbociclib (DRUG), ribociclib (DRUG).
Who is sponsoring clinical trial NCT06760637?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06760637 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06760637's enrollment target sits among peer trials
1,020 117th of 1224 higher than 1,107 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
- NCT06697600 · 1,020 participants · NA
A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT07216703 · 1,023 participants · Phase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI